Review
Immunology
Paul Curtiss, Amanda M. Walker, Benjamin F. Chong
Summary: This study reviewed patient cohorts and populations to investigate the progression of cutaneous lupus to systemic lupus. The study found variations in the progression rates between adult and pediatric groups, which were attributed to differences in patient populations, study design, diagnostic criteria, and follow-up time. Risk factors associated with the development of systemic lupus included positive anti-nuclear antibodies, hematologic abnormalities, and a higher number of lupus classification criteria at baseline.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Qian Chen, Jie Wang, Mengmeng Xiang, Yilun Wang, Zhixiong Zhang, Jun Liang, Jinhua Xu
Summary: This review summarizes the potential links between ferroptosis and systemic lupus erythematosus (SLE), elucidates the role of ferroptosis in SLE pathogenesis, and proposes a new therapeutic strategy for SLE.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Valeria Rella, Cinzia Rotondo, Alberto Altomare, Francesco Paolo Cantatore, Addolorata Corrado
Summary: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a wide range of clinical manifestations. Dysregulation of the immune system due to genetic, hormonal, and environmental factors can lead to various complications, including bone involvement such as osteoporosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Limin Liu, Longyuan Hu, Haojun Long, Meiling Zheng, Zhi Hu, Ye He, Xiaofei Gao, Pei Du, Hongjun Zhao, Di Yu, Qianjin Lu, Ming Zhao
Summary: The study identified IL21-AS1 as a regulator of Tfh cell differentiation and autoimmune response. Through epigenetic mechanisms, IL21-AS1 activates IL21 transcription to promote germinal center response, shedding light on the molecular regulation of autoimmune pathogenesis and providing a potential new target for treating SLE.
CLINICAL AND TRANSLATIONAL MEDICINE
(2022)
Review
Immunology
Swayanka Biswas, Katja Bieber, Rudolf Armin Manz
Summary: IL-10 is a cytokine that has pleiotropic effects on immune cells, including both suppressive and activating functions. It plays a dual role in Systemic lupus Erythematosus (SLE), inhibiting pro-inflammatory effector functions while also promoting extrafollicular antibody response. IL-10 is produced by B cells, myeloid cells, and certain T cell subsets, and it drives B cell responses, proliferation, class switching, and plasma cell formation.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Jae Il Shin, Keum Hwa Lee, Seoyeon Park, Jae Won Yang, Hyung Ju Kim, Kwanhyuk Song, Seungyeon Lee, Hyeyoung Na, Yong Jun Jang, Ju Yun Nam, Soojin Kim, Chaehyun Lee, Chanhee Hong, Chohwan Kim, Minhyuk Kim, Uichang Choi, Jaeho Seo, Hyunsoo Jin, BoMi Yi, Se Jin Jeong, Yeon Ook Sheok, Haedong Kim, Sangmin Lee, Sangwon Lee, Young Soo Jeong, Se Jin Park, Ji Hong Kim, Andreas Kronbichler
Summary: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with various manifestations, including pleuropulmonary involvement. The precise mechanism of pleuropulmonary involvement in SLE is not well-understood, but type 1 interferons, immune complexes, and neutrophils likely play important roles. There are multiple types of pleuropulmonary involvement, and various diagnostic tools and immunosuppressive therapies are used. However, specific therapies for pleuropulmonary involvement in SLE remain limited.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Rheumatology
May Yee Choi, Ann Elaine Clarke, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Ken Kalunian, Soren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Jill P. Buyon, Karen H. Costenbader, Marvin J. Fritzler
Summary: In a longitudinal analysis of a large international incident SLE cohort, three ANA assays demonstrated high positivity rates and commutability. However, over a 5-year follow-up, there was a modest variation in ANA assay performance.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
May Yee Choi, Irene Chen, Ann Elaine Clarke, Marvin J. Fritzler, Katherine A. Buhler, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David Alan Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Kenneth Kalunian, Soren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Jill P. Buyon, David Sontag, Karen H. Costenbader
Summary: A novel longitudinal clustering technique was used to analyze comprehensive autoantibody data from a large, well-characterised, multinational inception SLE cohort, in order to determine predictive profiles of clinical outcomes.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Immunology
Juan Liu, Xiaomin Zhang, Xuetao Cao
Summary: This review discusses the activation and functional changes of dendritic cells (DCs) during the development of systemic lupus erythematosus (SLE) and explores the therapeutic potential of targeting DCs in the treatment of SLE.
JOURNAL OF AUTOIMMUNITY
(2022)
Review
Pharmacology & Pharmacy
Xirui Guo, Xuerong Yang, Qi Li, Xiaoyan Shen, Huiyun Zhong, Yong Yang
Summary: Systemic lupus erythematosus (SLE) is a chronic diffuse connective tissue illness characterized by multisystem and multiorgan involvement. Intake of probiotics alters the composition of the gut microbiome, contributing to prevent the progression of SLE and alleviate symptoms in animal models. Probiotics supplementation may serve as a potentially novel approach in the treatment of SLE.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Madhu Ramaswamy, Raj Tummala, Katie Streicher, Andre Nogueira da Costa, Philip Z. Brohawn
Summary: Systemic lupus erythematosus (SLE) presents a challenging treatment landscape due to its multifaceted etiology and complex immunopathogenesis. While targeting the B-cell pathway has limitations, recent approval of anifrolumab, a type I interferon-blocking antibody, highlights the therapeutic potential of targeting the dysregulated interferon pathway in SLE patients. Further research into the pleiotropic biology of interferons and their intersection with SLE disease pathology will be crucial for the development of effective targeted therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Rheumatology
Mary K. Crow
Summary: Research has identified type I interferon (IFN-I) and autoantibodies targeting nucleic acids and nucleic acid-binding proteins as fundamental contributors to the pathogenesis of systemic lupus erythematosus (SLE). This review summarizes recent genetic analyses of SLE patients and current studies on innate and adaptive immune function, which contribute to sustained IFN-I pathway activation, immune activation, autoantibody production, inflammatory mediator generation, and tissue damage. The goal of these studies is to understand disease mechanisms, identify therapeutic targets, and develop better treatments for patients.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Immunology
Morgane Humbel, Florence Bellanger, Alice Horisberger, Madeleine Suffiotti, Natalia Fluder, Mariko Makhmutova, Amandine Mathias, Renaud Du Pasquier, Craig Fenwick, Camillo Ribi, Denis Comte
Summary: This study identified an immune signature for systemic lupus erythematosus (SLE) based on the expression of signaling lymphocytic activation molecule family (SLAMF) receptors on peripheral blood mononuclear cells (PBMC). The frequency of SLAMF1+ B cells, SLAMF4+ monocytes, and SLAMF4+ NK showed correlations with disease activity. Consensus clustering analysis also identified two cell clusters, SLESMB and SLEcTFH, which were significantly increased in SLE compared to controls.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Daniele Mauro, Sotiria Manou-Stathopoulou, Felice Rivellese, Elisabetta Sciacca, Katriona Goldmann, Victoria Tsang, Isabelle Lucey-Clayton, Sara Pagani, Farah Alam, Debasish Pyne, Ravindra Rajakariar, Patrick A. Gordon, James Whiteford, Michele Bombardieri, Costantino Pitzalis, Myles J. Lewis
Summary: Study finds that UBE2L3 plays a critical role in TLR7-mediated NF-??B activation in Systemic Lupus Erythematosus (SLE). Inhibition of UBE2L3 by Dimethyl Fumarate (DMF) can effectively suppress TLR7-induced NF-??B activation, B cell differentiation, and autoantibody production in SLE. This suggests that UBE2L3 inhibition could be a potential therapeutic strategy for SLE by repurposing DMF.
JOURNAL OF AUTOIMMUNITY
(2023)
Review
Immunology
Wei Sun, Pengchong Li, Jianping Cai, Jie Ma, Xuan Zhang, Yong Song, Yudong Liu
Summary: This article summarizes the altered lipid metabolism and its role in the pathogenesis and progression of SLE. Dysregulated lipid metabolism has complex effects on specific cell types, and may serve as a potential therapeutic target.
FRONTIERS IN IMMUNOLOGY
(2022)